CYP24A1 and neoplasm: The compounds have been investigated as inhibitors against four isozymes of CA comprising the cytosolic, ubiquitous isozymes hCA I and II as well as the transmembrane, tumour-associated isoforms hCA IX and XII which are validated antitumor targets.